BAXTER INTERNATIONAL INC (BAX)

Baxter International Inc., incorporated in Delaware in 1931, is a global healthcare company that develops, manufactures, and markets essential medical products used in hospitals, dialysis centers, nursing homes, ambulatory surgery centers, and homes under physician supervision. Its portfolio spans acute and chronic dialysis therapies, sterile IV solutions, infusion systems, parenteral nutrition, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, advanced surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. As of December 31, 2023, the company manufactured products in over 20 countries and sold them in more than 100 countries, employing approximately 60,000 people worldwide (41,000 in the U.S. and 19,000 internationally).

Following a 2022 strategic portfolio review, Baxter announced several major actions in January 2023: a proposed spinoff of its Kidney Care business (targeted for July 2024, generating $4.45 billion in net sales in both 2023 and 2022, about 30-31% of consolidated revenue) into an independent public company; implementation of a new operating model to streamline manufacturing and supply chain alignment; and divestiture of its BioPharma Solutions (BPS) business, completed in September 2023 for $3.96 billion in cash proceeds with a $2.88 billion pre-tax gain, used substantially to repay debt. As a result of the new operating model completed in Q3 2023, Baxter now reports four segments: Medical Products and Therapies (IV solutions, infusion systems, nutrition therapies, surgical hemostats/sealants), Healthcare Systems and Technologies (formerly Hillrom, encompassing smart beds, patient monitoring, respiratory devices, and surgical equipment), Pharmaceuticals (specialty injectables, inhaled anesthesia, compounding), and Kidney Care (dialysis and organ support therapies). The Hillrom acquisition, completed in December 2021 for $10.48 billion ($12.84 billion enterprise value), expanded Baxter's connected care offerings, though it also resulted in $2.81 billion of goodwill impairments and $332 million of intangible asset impairments in 2022.

Baxter's strategy centers on four pillars—innovation, market expansion, operational efficiency, and capital allocation—with a focus on deleveraging (targeting 2.75x net leverage by 2025), continued dividend payments, and eventual resumption of share repurchases, while remaining highly selective on acquisitions during this period. The company faces substantial competition across its segments, operates in a heavily regulated environment overseen by agencies such as the FDA, EMA, and CFDA, and is subject to healthcare cost containment pressures from governments, GPOs, IDNs, and managed care organizations globally. R&D expenditures were $667 million in 2023, up from $602 million in 2022 and $531 million in 2021, supporting facilities across Belgium, China, Germany, India, Italy, Japan, Sweden, and the U.S. Baxter also maintains a corporate responsibility framework anchored by a 2030 Commitment focused on patient empowerment, environmental protection, and community/employee support, alongside human capital management programs emphasizing competitive compensation, health and safety, and talent development.